
AstraZeneca, Daiichi Sankyo’s Enhertu impresses in 'game-changing' study with many cancers: #ASCO23
CHICAGO — AstraZeneca and Daiichi Sankyo’s Enhertu showed promising efficacy in a range of cancers — particularly gynecologic cancers — that express the biomarker HER2, according to a study released at ASCO’s annual meeting on Monday.
The Phase II, open-label trial could pave the way for Enhertu for a number of new indications down the line, such as endometrial and cervical cancers, and in cancers where HER2 testing is not the norm.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.